Andrey Espinoza, MD
Basic profileAdvanced Heart and Vascular Institute of Hunterdon
Andrey Espinoza is a Cardiology physician affiliated with Advanced Heart and Vascular Institute of Hunterdon. OpenAlex indexes 21 publications with 1,021 citations (h-index 12).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
73.2%Statin18.5%Rosuvastatin Calcium49%Atorvastatin Calcium41%Simvastatin6%Pravastatin Sodium3%Livalo1%Part D<11 patientsBeta blocker15.2%Metoprolol Succinate62%Metoprolol Tartrate13%Carvedilol13%Sotalol3%Labetalol Hcl3%Nebivolol Hcl3%Atenolol2%Propranolol Hcl1%Carvedilol Er1%Part D<11 patients+ 21 more classes in this area
Blood & clotting
18.3%Factor Xa inhibitor10.7%Eliquis79%Xarelto21%Part D≥146 patientsP2Y12 inhibitor6.3%Clopidogrel94%Brilinta6%Part D<11 patients+ 2 more classes in this area
Nervous system
7.6%Opioid Agonist5.2%Fentanyl citrate100%Part B, office-administered≥43 patientsBenzodiazepine2.4%Midazolam hydrochloride87%Temazepam13%Part D + Part B<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 2025 SCAI Clinical Practice Guidelines for the Management of Chronic Venous Disease
Journal of the Society for Cardiovascular Angiography & Interventions
2025 - Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - PB0437 Concordance of Phosphatidylserine/Prothrombin and APhL Antibodies Associated with Antiphospholipid Syndrome-Associated Pregnancy Morbidity
Research and Practice in Thrombosis and Haemostasis
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”